Product Description
KPG-818 significantly inhibits tumor growth in MM.1S multiple myeloma, WSU-DLCL-2 diffuse large B cell lymphoma, DOHH-2 follicular lymphoma, REC-1 mantle cell lymphoma xenograft models. Importantly, KPG-818 prolongs the survival of the mouse cohorts bearing systemic human H929 multiple myeloma in a dose-dependent manner. Moreover, KPG-818 shows favorable DMPK and toxicity profiles in pre-clinical IND enabling studies. (Sourced from: https://aacrjournals.org/cancerres/article/80/16_Supplement/6367/640997/Abstract-6367-KPG-818-a-novel-cereblon-modulator)
Mechanisms of Action: CRBN Modulator,IKZF1 Inducer,IKZF3 Inducer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kangpu Biopharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Lupus Erythematosus, Systemic
Phase 1: Adult T-Cell Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Multiple Myeloma|T-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
KPG-818-HEM-101 | P1 |
Recruiting |
T-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Chronic Lymphoid Leukemia|Hodgkin Lymphoma|Multiple Myeloma|Adult T-Cell Leukemia-Lymphoma|Diffuse Large B-Cell Lymphoma |
2024-10-01 |
21% |
Lupus | P2 |
Completed |
Lupus Erythematosus, Systemic |
2023-08-18 |
49% |